Physician profile
Jill C Ingelse
NPI 1528058443
$2,231.35
in general payments reported to CMS, 2019-2025
14 companies · $218 in 2025
The $218 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2020: $24.95 · 2021: $35.79 · 2022: $162 · 2023: $80.45 · 2024: $1,557 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,018 · Food and Beverage: $838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,017.86 |
| Food and Beverage | $837.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,363.84 | 2021-2024 | |
| Glaukos Corporation | $255.17 | 2024-2025 | Photrexa Viscous and Photrexa, Photrexa |
| Coopervision INC. | $137.97 | 2024-2025 | Myday Contact Lens |
| Johnson & Johnson Vision Care, INC. | $132.86 | 2019-2023 | Acuvue |
| Abb Con-Cise Optical Group LLC | $87.31 | 2022-2023 | Spectacle Lenses, Contact Lens |
| Shire North American Group INC | $53.21 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $52.98 | 2025 | Xdemvy |
| Oyster Point Pharma, INC. | $32.90 | 2022-2023 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $31.80 | 2019-2022 | |
| Maculogix, INC. | $22.35 | 2019-2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $19.02 | 2019 | |
| Allergan, INC. | $14.68 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $14.25 | 2022 | |
| Biotissue Holdings INC. | $13.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jill Ingelse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.